Form 4: Trevi Therapeutics Officer Granted Stock Options

Christopher Galletta, Controller and Principal Accounting Officer of Trevi Therapeutics, Inc., was granted stock options to purchase 41,000 shares of common stock on February 18, 2025.

Summary

• Christopher Galletta, an officer at Trevi Therapeutics, Inc., received stock options on February 18, 2025.
• The options grant him the right to purchase 41,000 shares of Trevi Therapeutics' common stock at an exercise price of $4.22 per share.
• The options vest over a period of four years, with 25% vesting on February 18, 2026, and the remaining 75% vesting in equal monthly installments until February 18, 2029.
• The options expire on February 17, 2035.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a stock option grant. It's a standard corporate practice, so neither particularly positive nor negative.

Positives

• The granting of stock options to an officer aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages long-term commitment from the officer.

Future Outlook

There is no future outlook provided in this document.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to attract and retain talent, aligning employee incentives with company performance.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech and pharmaceutical industries.
• Vesting schedules, such as the one described in the document (25% after one year, then monthly), are typical to ensure long-term commitment.
• Comparable companies like Cara Therapeutics or Vanda Pharmaceuticals also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for management.
• Employees may see this as a positive sign of the company investing in its personnel.

Key Dates

Keywords

stock options, Form 4, insider trading, Trevi Therapeutics, TRVI, Christopher Galletta, equity compensation